

Publisher: Adis International
ISSN: 0114-9954
Source: Reactions Weekly, Vol.1, Iss.1267, 2009-01, pp. : 3-3
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


US FDA reviewing safety of ezetimibe/simvastatin
Reactions Weekly, Vol. 1, Iss. 1217, 2008-01 ,pp. :


US FDA reviewing safety of ezetimibe/simvastatin
Inpharma, Vol. 1, Iss. 1653, 2008-01 ,pp. :


FDA is reviewing safety of omalizumab
Reactions Weekly, Vol. 1, Iss. 1262, 2009-01 ,pp. :


US FDA reviewing safety of botulinum toxin type A and B
Reactions Weekly, Vol. 1, Iss. 1189, 2008-01 ,pp. :


The US FDA is reviewing the safety of angiotensin receptor blockers (ARBs)
Reactions Weekly, Vol. 1, Iss. 1311, 2010-01 ,pp. :